TABLE 3.
Overview of IC Efficacy in All Evaluable Patients With the Selected Clinical Scenario
| Clinical Characteristic | Patient, No. | IC Response,a No. (%) | IC BOR,a No. (%) | ||||
|---|---|---|---|---|---|---|---|
| CR | PR | SD | PD | NE | |||
| Patients with focal LMD | 4 | 1 (25.0) | 0 (0) | 1 (25.0) | 2 (50.0) | 0 (0) | 1 (25.0) |
| Patients undergoing concurrent SRS with adagrasib | 3 | 2 (66.7) | 0 (0) | 2 (66.7) | 0 (0) | 1 (33.3) | 0 (0) |
| Patients with no previous systemic therapy | 4 | 2 (50.0) | 2 (50.0) | 0 (0) | 1 (25.0) | 0 (0) | 1 (25.0) |
| Patients with a dose reductionb | 7c | 4 (57.1) | 1 (14.3) | 3 (42.9) | 2 (28.6) | 1 (14.3) | 0 (0) |
| Patients with comutations at baseline | 13 | 5 (38.5) | 1 (7.7) | 4 (30.8) | 7 (53.8) | 0 (0) | 1 (7.7) |
Abbreviations: BOR, best overall response; CR, complete response; IC, intracranial; LMD, leptomeningeal disease; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease; SRS, stereotactic radiosurgery.
a
Assessed by CNS RECIST.
b
Includes patients who received 400 mg twice a day for the majority of their treatment (n = 5); patients who received 200 mg twice a day for most of their treatment (n = 1); and patients with multiple dose reductions throughout their treatment (n = 1).
c
All patients who were radiographically evaluable.